Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Kim D, Burkhardt R, Alperstein SA, Gokozan HN, Goyal A, Heymann JJ, et al. Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study. Cancer Cytopathol. 2022;130(8):630-639.

Aguilar RR, Shen Z-, Tyler JK. A Simple, Improved Method for Scarless Genome Editing of Budding Yeast Using CRISPR-Cas9. Methods Protoc. 2022;5(5).

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.

Singhal S, Hellyer J, Ouseph MM, Wakelee HA, Padda SK. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clin Res Rep. 2022;3(5):100323.

Ullmann TM, Thiesmeyer JW, Lee YJ, Beg S, Mosquera JM, Elemento O, et al. RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype. Ann Surg Oncol. 2022.

Grossman M, Ruan J, Magro C. Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. JAAD Case Rep. 2022;25:58-62.

Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. J Biomed Sci. 2022;29(1):13.

Karajannis MA, Li BK, Souweidane MM, Liechty B, Yao J, Benhamida JK, et al. YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma. Acta Neuropathol Commun. 2022;10(1):117.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.